biologics in development or approved under regulatory processes without the rigorous evaluation of biosimilarity defined by the EMA, FDA, or WHO guidelines are not included in this table; EMA, European Medicines Agency; FDA, US Food and Drug Administration; NHL, non-Hodgkin’s lymphoma; PK, pharmacokinetics; RA, rheumatoid arthritis; WHO, World Health Organization.